HighTower Advisors LLC Invests $12.04 Million in Inhibrx, Inc. (NASDAQ:INBX)

HighTower Advisors LLC bought a new position in Inhibrx, Inc. (NASDAQ:INBX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 781,752 shares of the company’s stock, valued at approximately $12,039,000. HighTower Advisors LLC owned approximately 5.40% of Inhibrx as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. bought a new position in shares of Inhibrx in the 4th quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Inhibrx in the 4th quarter worth approximately $47,000. New York State Common Retirement Fund purchased a new stake in shares of Inhibrx in the 4th quarter worth approximately $53,000. Exchange Traded Concepts LLC purchased a new stake in shares of Inhibrx in the 4th quarter worth approximately $148,000. Finally, Rhumbline Advisers purchased a new stake in shares of Inhibrx in the 4th quarter worth approximately $228,000. Institutional investors own 82.46% of the company’s stock.

Inhibrx Stock Performance

Inhibrx stock opened at $14.10 on Monday. The stock’s 50 day moving average is $13.38 and its 200 day moving average is $14.67. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $35.42.

Analysts Set New Price Targets

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.